DrugPatentWatch Database Preview
Drugs in Development Information for Bavituximab
» See Plans and Pricing
What is the drug development status for Bavituximab?
Bavituximab is an investigational drug.
There have been 26 clinical trials for Bavituximab.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2013.
The most common disease conditions in clinical trials are Carcinoma, Lung Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Peregrine Pharmaceuticals, University of Texas Southwestern Medical Center, and Merck Sharp & Dohme Corp.
There are thirty-six US patents protecting this investigational drug and eight hundred and forty-six international patents.
Summary for Bavituximab
| US Patents | 36 |
| International Patents | 846 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2013-12-01) |
| Vendors | 0 |
Recent Clinical Trials for Bavituximab
| Title | Sponsor | Phase |
|---|---|---|
| 1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck | University of Maryland, Baltimore | Phase 2 |
| An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients | Merck Sharp & Dohme Corp. | Phase 2 |
| An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients | Oncologie Inc. | Phase 2 |
Clinical Trial Summary for Bavituximab
Top disease conditions for Bavituximab
Top clinical trial sponsors for Bavituximab
US Patents for Bavituximab
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Bavituximab | Start Trial | Multispecific constructs | AbbVie Stemcentrx LLC (North Chicago, IL) | Start Trial |
| Bavituximab | Start Trial | .beta.-glucan methods and compositions that affect the tumor microenvironment | BIOTHERA, INC. (Eagan, MN) | Start Trial |
| Bavituximab | Start Trial | Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein | CureVac AG (Tubingen, DE) | Start Trial |
| Bavituximab | Start Trial | Method of treating pancreatic cancer | ChemoCentryx, Inc. (Mountain View, CA) | Start Trial |
| Bavituximab | Start Trial | Compositions and methods for detecting protease activity in biological systems | CytomX Therapeutics, Inc. (South San Francisco, CA) | Start Trial |
| Bavituximab | Start Trial | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | First Wave Bio, Inc. (Ann Arbor, MI) | Start Trial |
| Bavituximab | Start Trial | Methods of treating pancreatic cancer | ChemoCentryx, Inc. (Mountain View, CA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Bavituximab
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Bavituximab | Canada | CA2900764 | 2033-02-08 | Start Trial |
| Bavituximab | European Patent Office | EP2954056 | 2033-02-08 | Start Trial |
| Bavituximab | Hong Kong | HK1218930 | 2033-02-08 | Start Trial |
| Bavituximab | Japan | JP2016509014 | 2033-02-08 | Start Trial |
| Bavituximab | World Intellectual Property Organization (WIPO) | WO2014124326 | 2033-02-08 | Start Trial |
| Bavituximab | China | CN106687122 | 2034-07-10 | Start Trial |
| Bavituximab | China | CN107106593 | 2034-07-10 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
